The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. A large-scale clinical trial found ...
Research led by Penn Dental's Henry Daniell investigates the use of a lettuce-based, plant-encapsulated delivery platform as a new oral delivery of two GLP-1 drugs previously approved by the FDA in ...
The emergence of peptide therapeutics marks a transformative shift in the types of products being developed and manufactured in the pharmaceutical industry. Peptides, defined by the FDA as biopolymers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results